Related Experiment Video
Updated: May 2, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment
Sarah J Hardcastle1, Ellen Legge, Chris S Laundy
1School of Sport and Service Management, University of Brighton, Denton Road, Eastbourne, East Sussex, BN20 7SP, UK.
Insights
Familial hypercholesterolemia (FH) is a genetic disorder increasing heart disease risk. Patients perceive medication as sufficient, leading to low screening adherence among relatives, necessitating professional-led recruitment for better cascade screening outcomes.
Area of Science:
- Genetics
- Cardiology
- Public Health
Background:
- Familial hypercholesterolemia (FH) is a prevalent genetic disorder impacting 1 in 300-500 individuals.
- It is characterized by elevated LDL cholesterol, significantly increasing the risk of early-onset coronary heart disease (CHD) and premature mortality.
- Untreated FH poses a >50% CHD risk for men by age 50 and a 30% risk for women by age 60.
Purpose of the Study:
- To explore the perceptions and experiences of FH patients undergoing genetic cascade screening.
- To understand factors influencing adherence to health-protective behaviors and perceptions of genetic screening in FH.
- To address the low detection rate of FH despite effective management options.
Main Methods:
- Face-to-face interviews were conducted with 18 FH patients.
- Assessed patient knowledge and understanding of FH.
- Explored adherence to health behaviors and perceptions of genetic screening.
Main Results:
- Participants recognized FH as a serious genetic condition with risks of CHD and premature death.
- Many underestimated FH severity and lifestyle changes, relying on medication.
- Relatives were reluctant to screen due to fatalism or low motivation, with patients lacking influence for recruitment.
- Patients desired greater hospital support for contacting relatives.
Conclusions:
- Direct recruitment by medical professionals is recommended for cascade screening, leveraging their perceived authority.
- Clinicians must provide clear information on FH seriousness and adherence to medication and lifestyle changes, especially for asymptomatic individuals.
Background:
Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol levels, substantially increased risk of early-onset coronary heart disease (CHD) and premature mortality. If FH is untreated, it leads to a greater than 50 % risk of CHD in men by the age of 50 and at least 30 % in women by the age of 60. FH can be diagnosed through genetic screening and effectively managed through pharmacological treatment and lifestyle changes.
Purpose:
Familial hypercholesterolemia (FH) is a genetic health condition that increases the risk of cardiovascular disease. Although FH can be effectively managed with appropriate pharmacological and dietary interventions, FH detection rate through genetic screening remains low. The present study explored perceptions and experiences of FH patients (N = 18) involved in a genetic cascade screening programme.
Methods:
Face-to-face interviews were conducted to assess patients' knowledge and understanding of FH, explore factors linked to adherence to health-protective behaviours and examine perceptions of genetic screening.
Results:
Thematic analysis of interviews revealed four themes: disease knowledge, severity of FH, lifestyle behavioural change and barriers to cascade screening and treatment. Participants recognised FH as a permanent, genetic condition that increased their risk of CHD and premature mortality. Many participants dismissed the seriousness of FH and the importance of lifestyle changes because they perceived it to be effectively managed through medication. Despite positive attitudes toward screening, many participants reported that relatives were reluctant to attend screening due to their relatives' 'fatalistic' outlook or low motivation. Participants believed that they had insufficient authority or control to persuade family members to attend screening and welcomed greater hospital assistance for contact with relatives.
Conclusions:
Findings support the adoption of direct methods of recruitment to cascade screening led by medical professionals, who were perceived as having greater authority. Other implications included the need for clinicians to provide clear information, particularly to those who are asymptomatic, related to the seriousness of FH and the necessity for adherence to medication and lifestyle changes.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis III: Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Chronic Pancreatitis II: Collaborative Care
Assessment:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Atherosclerosis IV: Nursing Management
